Olivia A. Robles‐Rodríguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Olivia A. Robles‐Rodríguez has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ana María Salinas-Martínez
Universidad Autónoma de Nuevo León, School of Public Health, Monterrey, Mexico; Instituto Mexicano del Seguro Social. Epidemiological and Health Services Research Unit, Northeastern Biomedical Research Center, Monterrey, Mexico
1 shared publication - Consuelo Treviño-Garza
Department of Pediatrics, Hospital Universitario “Dr. Jose E. Gonzalez”, Autonomous University of Nuevo León, Monterrey 64460, Mexico
1 shared publication - Denise Garza‐Carrillo
Health Services of the State of Nuevo Leon, Ministry of Health Monterrey Nuevo León Mexico
1 shared publication - Edgar Paolo Rodríguez Vidales
Departamento de Enseñanza, Hospital Hospitaria, Escobedo, Nuevo León, Monterrey, Mexico
1 shared publication - Jose Juan Perez-Trujillo
Histology Department, Faculty of Medicine, Universidad Autonoma de Nuevo Leon (UANL), Monterrey, México
1 shared publication - Manuel E. de la O-Cavazos
Servicio de Neonatología del Hospital Universitario "Dr. José Eleuterio González" de la UANL Monterrey, N.L. México
1 shared publication
Latest Publications
- Open Access
- 7 June 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (10) , 5873-5879
Prevalence of IgG antibodies induced by the SARS‐COV‐2 virus in asymptomatic adults in Nuevo Leon, Mexico
Population‐based immunoglobulin G (IgG) seroprevalence studies in asymptomatic individuals in Latin America are scarce. The objective of the study was to estimate the prevalence and geographic distribution of IgG antibodies induced by natural SARS‐CoV‐2 infection in asymptomatic adults, 5–8 months after the first case was reported in a northeastern state of Mexico. This was a population‐based cross‐sectional study carried out in Nuevo Leon during August–November 2020. Individuals ≥18 years with no previous diagnosis or symptoms suggestive of COVID‐19 were consecutively screened in one of the busiest subway stations. Also, a search for eligible individuals was done from house‐to‐house, after selecting densely populated geographic sectors of each of the municipalities of the metropolitan area (n = 4495). The IgG antibodies to SARS‐CoV‐2 nucleocapsid protein were analyzed. The IgG antibody positivity rate was 27.1% (95% confidence interval [CI]: 25.8, 28.4); there were no differences by sex or age (p > 0.05). Analysis by month showed a gradual increase from 11.9% (August) to 31.9% (November); Week 39 had the highest positivity rate (42.2%, 95% CI: 34.2, 50.7). Most people did not have evidence of previous SARS‐CoV‐2 infection. Preventive measures and promotion of the COVID‐19 vaccine should be strengthened.
- 7 June 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (10) , 5873-5879
Open AccessPrevalence of IgG antibodies induced by the SARS‐COV‐2 virus in asymptomatic adults in Nuevo Leon, Mexico
Population‐based immunoglobulin G (IgG) seroprevalence studies in asymptomatic individuals in Latin America are scarce. The objective of the study was to estimate the prevalence and geographic distribution of IgG antibodies induced by natural SARS‐CoV‐2 infection in asymptomatic adults, 5–8 months after the first case was reported in a northeastern state of Mexico. This was a population‐based cross‐sectional study carried out in Nuevo Leon during August–November 2020. Individuals ≥18 years with no previous diagnosis or symptoms suggestive of COVID‐19 were consecutively screened in one of the busiest subway stations. Also, a search for eligible individuals was done from house‐to‐house, after selecting densely populated geographic sectors of each of the municipalities of the metropolitan area (n = 4495). The IgG antibodies to SARS‐CoV‐2 nucleocapsid protein were analyzed. The IgG antibody positivity rate was 27.1% (95% confidence interval [CI]: 25.8, 28.4); there were no differences by sex or age (p > 0.05). Analysis by month showed a gradual increase from 11.9% (August) to 31.9% (November); Week 39 had the highest positivity rate (42.2%, 95% CI: 34.2, 50.7). Most people did not have evidence of previous SARS‐CoV‐2 infection. Preventive measures and promotion of the COVID‐19 vaccine should be strengthened.